Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy.
Egeler M, Lai-Kwon J, Tissier R, Fraterman I, Kuijpers A, Van Houdt W, Wilgenhof S, Rao A, Sandhu S, Lee R, Eriksson H, van Leeuwen M, de Ligt K, van Akkooi A, van de Poll-Franse L. Egeler M, et al. Among authors: fraterman i. Eur J Cancer. 2024 Mar;200:113601. doi: 10.1016/j.ejca.2024.113601. Epub 2024 Feb 4. Eur J Cancer. 2024. PMID: 38340383
An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial.
Fraterman I, Wollersheim BM, Tibollo V, Glaser SLC, Medlock S, Cornet R, Gabetta M, Gisko V, Barkan E, di Flora N, Glasspool D, Kogan A, Lanzola G, Leizer R, Mallo H, Ottaviano M, Peleg M, van de Poll-Franse LV, Veggiotti N, Śniatała K, Wilk S, Parimbelli E, Quaglini S, Rizzo M, Locati LD, Boekhout A, Sacchi L, Wilgenhof S. Fraterman I, et al. JMIR Res Protoc. 2023 Oct 11;12:e49252. doi: 10.2196/49252. JMIR Res Protoc. 2023. PMID: 37819691 Free PMC article.
"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care.
Egeler MD, Boomstra E, Rohaan MW, Van den Heuvel NMJ, Fraterman I, Delfos M, van de Poll-Franse LV, Borch TH, Svane IM, Haanen JBAG, Retèl VP, Boekhout AH. Egeler MD, et al. Among authors: fraterman i. J Cancer Surviv. 2023 Aug 22. doi: 10.1007/s11764-023-01452-8. Online ahead of print. J Cancer Surviv. 2023. PMID: 37606816
Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review.
Egeler MD, van Leeuwen M, Fraterman I, van den Heuvel NMJ, Boekhout AH, Lai-Kwon J, Wilthagen EA, Eriksson H, Haanen JB, Wilgenhof S, Ascierto PA, van Akkooi ACJ, van de Poll-Franse LV. Egeler MD, et al. Among authors: fraterman i. Crit Rev Oncol Hematol. 2023 Mar;183:103919. doi: 10.1016/j.critrevonc.2023.103919. Epub 2023 Feb 1. Crit Rev Oncol Hematol. 2023. PMID: 36736511 Review.
Visualization formats of patient-reported outcome measures in clinical practice: a systematic review about preferences and interpretation accuracy.
Albers EAC, Fraterman I, Walraven I, Wilthagen E, Schagen SB, van der Ploeg IM, Wouters MWJM, van de Poll-Franse LV, de Ligt KM. Albers EAC, et al. Among authors: fraterman i. J Patient Rep Outcomes. 2022 Mar 3;6(1):18. doi: 10.1186/s41687-022-00424-3. J Patient Rep Outcomes. 2022. PMID: 35239055 Free PMC article.
A review of AI and Data Science support for cancer management.
Parimbelli E, Wilk S, Cornet R, Sniatala P, Sniatala K, Glaser SLC, Fraterman I, Boekhout AH, Ottaviano M, Peleg M. Parimbelli E, et al. Among authors: fraterman i. Artif Intell Med. 2021 Jul;117:102111. doi: 10.1016/j.artmed.2021.102111. Epub 2021 May 24. Artif Intell Med. 2021. PMID: 34127240 Free article. Review.